For the quarter ending 2025-09-30, IOBT made $8,198K in revenue. -$8,378K in net income. Net profit margin of -102.20%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 13,742 | 16,652 | ||
| General and administrative | 5,613 | 6,518 | ||
| Total operating expenses | 19,355 | 23,170 | ||
| Loss from operations | -19,355 | -23,170 | ||
| Currency exchange gain (loss), net | 98 | -374 | ||
| Interest income | 255 | 285 | ||
| Interest expense | 886 | 253 | ||
| Change in fair value of warrants (note 3) | -9,846 | 2,587 | ||
| Total other income (expense), net | 9,313 | -2,929 | ||
| Loss before income tax expense (credit) | -10,042 | -26,099 | ||
| Income taxes expense | - | 118 | ||
| Income tax (credit) expense | -1,664 | 118 | ||
| Net loss | -8,378 | -26,217 | ||
| Net loss attributable to common shareholders | -8,378 | -26,217 | ||
| Net loss per common share, basic | -0.13 | -0.4 | ||
| Net loss per common share, diluted | -0.13 | -0.4 | ||
| Weighted-average number of shares used in computing net loss per common share, basic | 66,941,964 | 65,880,914 | ||
| Weighted-average number of shares used in computing net loss per common share, diluted | 66,941,964 | 65,880,914 | ||
IO Biotech, Inc. (IOBT)
IO Biotech, Inc. (IOBT)